Skip to main content

Table 1 Characteristics of included studies and evaluated sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials

From: Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis

First Author, year

Country

Study design

Patients (n)

Cardiovascular disease (%)

CANVAS

DECLARE-TIMI 58

EMPA-REG OUTCOME

VERTIS-CV

Birkeland, 2018 [23]

Germany, the Netherlands, Norway, Sweden

RCS

803,836

34

Canivell, 2019 [24]

Spain

RCS

373,185

23

Nicolucci, 2019 [25]

Italy

RCS

342,205

Shao, 2019 [26]

Taiwan

RCS

11,650

27

Wittbrodt, 2019 [27]

the United States of America

RCS

172,643

64

  1. RCS retrospective cohort study; – not reported